Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical’s subsidiary Chengdu Xingrui Jingxuan Therapeutics has initiated a Phase I clinical trial in mainland China for SRT-007, a theranostic radiopharmaceutical targeting PSMA-positive metastatic castration‑resistant prostate cancer, marking an advancement in the group’s oncology innovation pipeline. The SRT-007 project, which comprises Gallium [68Ga] PSMA-0057 for diagnostic use and Lutetium [177Lu] PSMA-0057 for therapeutic use, has attracted approximately RMB 32.19 million in R&D investment to date, underscoring Fosun Pharma’s commitment to nuclear medicine and potentially strengthening its competitive position in precision cancer diagnosis and treatment if subsequent trial stages prove successful.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a diversified Chinese healthcare group engaged in pharmaceutical research and development, manufacturing, and related medical services, with a growing focus on innovative therapies, including radiopharmaceuticals, to address major disease areas such as oncology in the domestic China market and beyond.
Average Trading Volume: 4,485,819
Technical Sentiment Signal: Buy
Current Market Cap: HK$74.45B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.